Radotinib in the treatment of chronic phase chronic myeloid leukemia patients
Posted 09 January 2015 - 07:21 AM
10/01/2014 100% Diagnosis (WBC 278k, Blasts 6%, Spleen extended 20cm)
Posted 09 January 2015 - 11:22 AM
Still early in clinical trials. Results are good but a rather high rate of drug interruptions and patients quitting the drug before 12 months:
71.4% of the patients had a dose interruption
42.9% of the patients discontinued treatment before 12 months
But more drug options is always good. Maybe it will have a niche role. Approval may be a couple years away. This drug is being developed by a Korean company, so it may be available in Asia earlier.
Posted 08 February 2016 - 06:04 PM
In CML: Radotinib as Frontline Therapy; Ponatinib Promising for T315I Patients
ORLANDO, Florida—Two tyrosine kinase inhibitors (TKIs)—one a new drug from Korea, the other designed to target hard-to-treat T315I mutations—show promise as potential treatments for chronic myeloid leukemia (CML) to replace imatinib or allogeneic stem cell transplant (SCT) in selected patients, according to two new studies presented here at the American Society of Hematology Annual Meeting.
1 user(s) are reading this topic
0 members, 1 guests, 0 anonymous users